Chemotherapy Drug Extravasation in Totally Implantable Venous Access Port Systems: How Effective is Early Surgical Lavage?

Purpose Totally implantable venous access port systems (TIVAPS) are a widely used and an essential tool in the efficient delivery of chemotherapy. Chemotherapy drug extravasation (CDE) can have dire consequences and will delay treatment. The purpose of this study is to both clarify the management of CDE and show the effectiveness of early surgical lavage (ESL). Methods Patients who had presented to the Cancer Center of Lille (France) with TIVAPS inserted between January 2004 and April 2013 and CDE had their medical records reviewed retrospectively. Results Thirty patients and 33 events were analyzed. Implicated agents were vesicants (51.5%), irritants (45.5%) and non-vesicants (3%). Huber needle malpositionning was involved in 27 cases. Surgery was performed in 97% of cases, 87.5% of which were for ESL with 53.1% of the latter requiring TIVAPS extraction. Six patients required a second intervention due to adverse outcomes (severe cases). Vesicants were found to be implicated in four out of six severe cases and oxaliplatin in two others. Extravasated volume was above 50 ml in 80% of cases. Only one patient required a skin graft. Conclusions CDEs should be managed in specialized centers. ESL allows for limited tissue contact of the chemotherapy drug whilst using a simple, widely accessible technique. The two main factors that correlate with adverse outcome seem to be the nature of the implicated agent (vesicants) and the extravasated volume (above 50 ml) leading to worse outcomes. Oxaliplatin should be considered as a vesicant.

[1]  Lazina Sharmin,et al.  Images in Clinical Medicine 5(3) , 2015 .

[2]  N. Roche,et al.  Extravasation Injuries: Current Medical and Surgical Treatment , 2013, Acta chirurgica Belgica.

[3]  A. Margulies,et al.  Management of chemotherapy extravasation: ESMO--EONS clinical practice guidelines. , 2012, European journal of oncology nursing : the official journal of European Oncology Nursing Society.

[4]  A. Kleontas,et al.  Totally implantable central venous access ports. Analysis of 700 cases , 2011, Journal of surgical oncology.

[5]  C. Fournier,et al.  Totally implantable venous access port systems and risk factors for complications: a one-year prospective study in a cancer centre. , 2011, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

[6]  P. Vogt,et al.  Subcutaneous wash-out procedure (SWOP) for the treatment of chemotherapeutic extravasations. , 2011, Journal of plastic, reconstructive & aesthetic surgery : JPRAS.

[7]  G. Heers,et al.  [Emergency open surgical treatment of extravasations of cytostatic agents in the upper extremity]. , 2009, Handchirurgie, Mikrochirurgie, plastische Chirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Handchirurgie : Organ der Deutschsprachigen Arbeitsgemeinschaft fur Mikrochirurgie der Peripheren Nerven und Gefasse : Organ der V....

[8]  P. Jaen,et al.  Images in clinical medicine. Extravasation of epirubicin. , 2009, The New England journal of medicine.

[9]  S. Vieni,et al.  Surgical treatment of extravasation injuries , 2005, Journal of surgical oncology.

[10]  H. Batirel,et al.  Complications and management of long-term central venous access catheters and ports , 2004, The journal of vascular access.

[11]  G. Martinelli,et al.  Use of totally implantable central venous access ports for high-dose chemotherapy and peripheral blood stem cell transplantation: results of a monocentre series of 376 patients. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[12]  P. Kosmidis,et al.  Prevention of tissue necrosis due to accidental extravasation of cytostatic drugs by a conservative approach , 2004, Cancer Chemotherapy and Pharmacology.

[13]  P. Boland,et al.  Vesicant characteristics of oxaliplatin following antecubital extravasation. , 2003, Clinical oncology (Royal College of Radiologists (Great Britain)).

[14]  P. Saip,et al.  Totally implantable venous-access ports: local problems and extravasation injury. , 2002, The Lancet. Oncology.

[15]  P. Witteveen,et al.  Totally implantable venous access devices: evaluation of complications and a prospective comparative study of two different port systems. , 2000, The Netherlands journal of medicine.

[16]  M. Baur,et al.  Extravasation of Oxaliplatin (Eloxatin®) – Clinical Course , 2000, Oncology Research and Treatment.

[17]  Viale Ph,et al.  Extravasation of infusate via implanted ports: two case studies. , 1999 .

[18]  J. Plukker,et al.  Complications of venous access ports in 132 patients with disseminated testicular cancer treated with polychemotherapy. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. Korn,et al.  Improved methods for venous access: the Port-A-Cath, a totally implanted catheter system. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  E. McFadden,et al.  Toxicity and response criteria of the Eastern Cooperative Oncology Group , 1982, American journal of clinical oncology.